Related references
Note: Only part of the references are listed.A Human Papillomavirus (HPV) In Vitro Neutralization Assay That Recapitulates the In Vitro Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies
Patricia M. Day et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals
Joseph G. Dauner et al.
MOLECULAR AND CELLULAR PROBES (2012)
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2011)
The Effect of Sample Handling on Cross Sectional HIV Incidence Testing Results
Oliver Laeyendecker et al.
PLOS ONE (2011)
MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
Eve Draper et al.
VACCINE (2011)
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
Troy J. Kemp et al.
VACCINE (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
Current understanding of the mechanism of HPV infection
John T. Schiller et al.
GYNECOLOGIC ONCOLOGY (2010)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
Cosette M. Wheeler et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
Troy J. Kemp et al.
VACCINE (2008)
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
Rolando Herrero et al.
VACCINE (2008)
Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions
Judith F. Smith et al.
HUMAN VACCINES (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Antiviral antibody responses: the two extremes of a wide spectrum
L Hangartner et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR
Leen-Jan van Doorn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Share Paper
